Evidence map›Paper›PMID 19369254›Full record

ArticleThe Journal of biological chemistry2009

APH1 polar transmembrane residues regulate the assembly and activity of presenilin complexes.

Raphaëlle Pardossi-Piquard, Seung-Pil Yang, Soshi Kanemoto, Yongjun Gu, Fusheng Chen, Christopher Böhm, Jean Sevalle, Tong Li, Philip C Wong, Frédéric Checler and 3 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Structural and Chemical Biology of Presenilin Complexes.Cold Spring Harbor perspectives in medicine · 2017
    Review
  7. Article
  8. Structural biology of presenilin 1 complexes.Molecular neurodegeneration · 2014
    Review
  9. Article
  10. The γ-secretase complex: from structure to function.Frontiers in cellular neuroscience · 2014
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 4 countries.

Raphaëlle Pardossi-PiquardFrom the Centre for Research in Neurodegenerative Diseases, Toronto, Ontario M5S 3H2, Canada.
Seung-Pil YangFrom the Centre for Research in Neurodegenerative Diseases, Toronto, Ontario M5S 3H2, Canada.
Soshi KanemotoFrom the Centre for Research in Neurodegenerative Diseases, Toronto, Ontario M5S 3H2, Canada.
Yongjun GuFrom the Centre for Research in Neurodegenerative Diseases, Toronto, Ontario M5S 3H2, Canada.
Fusheng ChenFrom the Centre for Research in Neurodegenerative Diseases, Toronto, Ontario M5S 3H2, Canada.
Christopher BöhmFrom the Centre for Research in Neurodegenerative Diseases, Toronto, Ontario M5S 3H2, Canada.
Jean SevalleInstitut de Pharmacologie Moléculaire et Cellulaire and Institut de NeuroMédecine Moléculaire of CNRS, Equipe Labellisée Fondation pour la Recherche Médicale, Valbonne 06560, France.
Tong LiDepartments of Neuroscience and Pathology, John Hopkins University School of Medicine, Baltimore, Maryland 21205.
Philip C WongDepartments of Neuroscience and Pathology, John Hopkins University School of Medicine, Baltimore, Maryland 21205.
Frédéric CheclerInstitut de Pharmacologie Moléculaire et Cellulaire and Institut de NeuroMédecine Moléculaire of CNRS, Equipe Labellisée Fondation pour la Recherche Médicale, Valbonne 06560, France.
Gerold Schmitt-UlmsFrom the Centre for Research in Neurodegenerative Diseases, Toronto, Ontario M5S 3H2, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 1L5, Canada.
Peter St George-HyslopFrom the Centre for Research in Neurodegenerative Diseases, Toronto, Ontario M5S 3H2, Canada; Department of Medicine (Division of Neurology), Toronto Western Hospital Research Institute, University Health Network, Toronto, Ontario M5T 2S8, Canada; Department of Clinical Neuroscience, University of Cambridge, Cambridge CB2 OXY, United Kingdom.
Paul E FraserFrom the Centre for Research in Neurodegenerative Diseases, Toronto, Ontario M5S 3H2, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2M9, Canada. Electronic address: paul.fraser@utoronto.ca.
Occupational Cancer Research Centre · CAJohns Hopkins University · USAddenbrooke's Hospital · GBCanada Research Chairs · CAFondation pour la Recherche Médicale · FRInstitut de Pharmacologie Moléculaire et Cellulaire · FROntario Institute for Cancer Research · CA

Funding

Nicastrin: Physiological Role and Therapeutic Target ValidationP01NS047308 · NINDS · JOHNS HOPKINS UNIVERSITY · PI WONG, PHILIP C · 2005 to 2009
$4.9M
Nicastrin and Presenilin-dependent gamma-secretaseR01NS045150 · NINDS · JOHNS HOPKINS UNIVERSITY · PI WONG, PHILIP C · 2003 to 2007
$1.9M
NINDS NIH HHS P01 NS047308NINDS NIH HHS R01 NS045150NINDS NIH HHS R01 NS45150Wellcome Trust 081864
6 · The paper itself

Abstract

Complexes involved in the gamma/epsilon-secretase-regulated intramembranous proteolysis of substrates such as the amyloid-beta precursor protein are composed primarily of presenilin (PS1 or PS2), nicastrin, anterior pharynx defective-1 (APH1), and PEN2. The presenilin aspartyl residues form the catalytic site, and similar potentially functional polar transmembrane residues in APH1 have been identified. Substitution of charged (E84A, R87A) or polar (Q83A) residues in TM3 had no effect on complex assembly or activity. In contrast, changes to either of two highly conserved histidines (H171A, H197A) located in TM5 and TM6 negatively affected PS1 cleavage and altered binding to other secretase components, resulting in decreased amyloid generating activity. Charge replacement with His-to-Lys substitutions rescued nicastrin maturation and PS1 endoproteolysis leading to assembly of the formation of structurally normal but proteolytically inactive gamma-secretase complexes. Substitution with a negatively charged side chain (His-to-Asp) or altering the structural location of the histidines also disrupted gamma-secretase binding and abolished functionality of APH1. These results suggest that the conserved transmembrane histidine residues contribute to APH1 function and can affect presenilin catalytic activity.

Indexed as

Amino Acid SequenceAmino Acid SubstitutionAmyloid Precursor Protein SecretasesAnimalsAspartic AcidCatalysisCells, CulturedConserved SequenceEndopeptidasesFibroblastsHistidineHumansMembrane ProteinsMiceMolecular Sequence DataMultiprotein ComplexesAmyloid Precursor Protein SecretasesAPH1A protein, humanAspartic AcidEndopeptidasesHistidineMembrane ProteinsMultiprotein ComplexesPeptide HydrolasesPresenilins

Identifiers

PMID19369254
PMCPMC2713549
OpenAlexW1968069499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.